Phospho-Estrogen Receptor alpha (Ser118) Antibody - #AF3061

Figure 6. The Eocc activates ERα to promote osteogenic activity: (A) Cell viability of MCF-7 cells treated with different concentrations of the Eocc (0, 0.1, 1, 10 µg/mL) for 24 h, assessed by the CCK-8 assay. Treatment with 1 µM of E2 was used as a positive control. (B) The dual luciferase reporter assay measuring the activation of ERα and ERβ. Treatment groups included different concentrations of the Eocc (0, 0.1, 1, 10 µg/mL), positive control E2 (1 µM), co-treatment with E2 and ICI 182,780 (1 µM), and co-treatment with 0.1 µg/mL of the Eocc and ICI 182,780 (1 µM). (C,D) Western blot analysis and quantification of ERα and p-ERα expression levels. (E,F) Representative images of ALP staining (n = 3). Magnified at 40× with a scale bar of 200 µm. (G,H) Representative images of osteogenic mineralization nodule staining (n = 3). Magnified at 40× with a scale bar of 200 µm. (I,J) Western blot analysis and the quantification of osteogenic marker proteins in MC3T3-E1 cells treated with the Eocc, with or without ERα inhibition. All bar graphs represent mean ± SD. Comparisons versus the control group are as follows: * p < 0.05, ** p < 0.01, *** p < 0.001; versus the normal group are as follows: ## p < 0.01, ### p < 0.001; and versus the E2 or E-1 group are as follows: & p < 0.05, && p < 0.01, &&& p < 0.001.